AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results
February 28, 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and...
The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company
February 23, 2022 16:29 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference
February 23, 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use
February 17, 2022 16:01 ET
|
AVITA Medical
System enhanced in response to clinician workflow and usability feedback; new system simplifies process United States product launch planned for Q2 2022 VALENCIA, Calif. and MELBOURNE,...
AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
February 15, 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 02, 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium
January 24, 2022 08:00 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021
January 10, 2022 08:00 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia., Jan. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and...
AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction
January 06, 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin Cells
January 06, 2022 08:00 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...